• Gene deletion; HGNC; HGNC:1787; CDKN2A; Zygosity=Homozygous (PubMed=27723727).
  

PubMed=25184684; DOI=10.1371/journal.pone.0106694; PMCID=PMC4153667
Holmberg Olausson K., Maire C.L., Haidar S., Ling J., Learner E., Nister M., Ligon K.L.
Prominin-1 (CD133) defines both stem and non-stem cell populations in CNS development and gliomas.
PLoS ONE 9:e106694.1-e106694.11(2014)

PubMed=27723727; DOI=10.1038/nbt.3697; PMCID=PMC5142231
Stevens M.M., Maire C.L., Chou N., Murakami M.A., Knoff D.S., Kikuchi Y., Kimmerling R.J., Liu H.-Y., Haidar S., Calistri N.L., Cermak N., Olcum S., Cordero N.A., Idbaih A., Wen P.Y.-C., Weinstock D.M., Ligon K.L., Manalis S.R.
Drug sensitivity of single cancer cells is predicted by changes in mass accumulation rate.
Nat. Biotechnol. 34:1161-1167(2016)

PubMed=34610309; DOI=10.1016/j.celrep.2021.109788
Stockslager M.A., Malinowski S., Touat M., Yoon J.C., Geduldig J., Mirza M., Kim A.S., Wen P.Y.-C., Chow K.-H., Ligon K.L., Manalis S.R.
Functional drug susceptibility testing using single-cell mass predicts treatment outcome in patient-derived cancer neurosphere models.
Cell Rep. 37:109788.1-109788.12(2021)